Study #2022-0462
A Phase 1B/2, Open-Label, Safety, Tolerability, and Efficacy Study of NC410 Plus Pembrolizumab For Participants with Advanced Unresectable And/or Metastatic Immune Checkpoint inhibitor (ICI) and Refractory Solid Tumors of ICI Naive MSS/MSI-LOW Solid Tumor
MD Anderson Study Status
Not Accepting
Treatment Agent
NC410, pembrolizumab
Description
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Study phase:
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.